Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 107

1.

Study design of ASPirin in Reducing Events in the Elderly (ASPREE): a randomized, controlled trial.

ASPREE Investigator Group..

Contemp Clin Trials. 2013 Nov;36(2):555-64. doi: 10.1016/j.cct.2013.09.014.

2.

Baseline Characteristics of Participants in the ASPREE (ASPirin in Reducing Events in the Elderly) Study.

McNeil JJ, Woods RL, Nelson MR, Murray AM, Reid CM, Kirpach B, Storey E, Shah RC, Wolfe RS, Tonkin AM, Newman AB, Williamson JD, Lockery JE, Margolis KL, Ernst ME, Abhayaratna WP, Stocks N, Fitzgerald SM, Trevaks RE, Orchard SG, Beilin LJ, Donnan GA, Gibbs P, Johnston CI, Grimm RH; ASPREE Investigator Group..

J Gerontol A Biol Sci Med Sci. 2017 Jan 20. doi: 10.1093/gerona/glw342. [Epub ahead of print]

PMID:
28329340
3.

Slowing the progression of age-related hearing loss: Rationale and study design of the ASPIRIN in HEARING, retinal vessels imaging and neurocognition in older generations (ASPREE-HEARING) trial.

Lowthian JA, Britt CJ, Rance G, Lin FR, Woods RL, Wolfe R, Nelson MR, Dillon HA, Ward S, Reid CM, Lockery JE, Nguyen TT, McNeil JJ, Storey E; ASPREE Investigators..

Contemp Clin Trials. 2016 Jan;46:60-6. doi: 10.1016/j.cct.2015.11.014.

PMID:
26611434
4.

Feasibility of conducting a primary prevention trial of low-dose aspirin for major adverse cardiovascular events in older people in Australia: results from the ASPirin in Reducing Events in the Elderly (ASPREE) pilot study.

Nelson MR, Reid CM, Ames DA, Beilin LJ, Donnan GA, Gibbs P, Johnston CI, Krum H, Storey E, Tonkin A, Wolfe R, Woods R, McNeil JJ.

Med J Aust. 2008 Jul 21;189(2):105-9.

PMID:
18637782
5.

A randomised controlled trial of low-dose aspirin for the prevention of fractures in healthy older people: protocol for the ASPREE-Fracture substudy.

Barker AL, McNeil JJ, Seeman E, Ward SA, Sanders KM, Khosla S, Cumming RG, Pasco JA, Bohensky MA, Ebeling PR, Woods RL, Lockery JE, Wolfe R, Talevski J; ASPREE Investigator Group..

Inj Prev. 2016 Aug;22(4):297-301. doi: 10.1136/injuryprev-2015-041655.

6.

Rationale for a trial of low-dose aspirin for the primary prevention of major adverse cardiovascular events and vascular dementia in the elderly: Aspirin in Reducing Events in the Elderly (ASPREE).

Nelson M, Reid C, Beilin L, Donnan G, Johnston C, Krum H, Storey E, Tonkin A, McNeil J; Aspirin in Reducing Events in the Elderly (ASPREE) Study Group,..

Drugs Aging. 2003;20(12):897-903.

PMID:
14565783
7.

Aspirin for prophylactic use in the primary prevention of cardiovascular disease and cancer: a systematic review and overview of reviews.

Sutcliffe P, Connock M, Gurung T, Freeman K, Johnson S, Kandala NB, Grove A, Gurung B, Morrow S, Clarke A.

Health Technol Assess. 2013 Sep;17(43):1-253. doi: 10.3310/hta17430. Review.

8.
9.

Continuation of low-dose aspirin therapy in peptic ulcer bleeding: a randomized trial.

Sung JJ, Lau JY, Ching JY, Wu JC, Lee YT, Chiu PW, Leung VK, Wong VW, Chan FK.

Ann Intern Med. 2010 Jan 5;152(1):1-9. doi: 10.7326/0003-4819-152-1-201001050-00179.

PMID:
19949136
10.

Aspirin for prevention of cardiovascular events in a general population screened for a low ankle brachial index: a randomized controlled trial.

Fowkes FG, Price JF, Stewart MC, Butcher I, Leng GC, Pell AC, Sandercock PA, Fox KA, Lowe GD, Murray GD; Aspirin for Asymptomatic Atherosclerosis Trialists..

JAMA. 2010 Mar 3;303(9):841-8. doi: 10.1001/jama.2010.221.

PMID:
20197530
11.

AspiriN To Inhibit SEPSIS (ANTISEPSIS) randomised controlled trial protocol.

Eisen DP, Moore EM, Leder K, Lockery J, McBryde ES, McNeil JJ, Pilcher D, Wolfe R, Woods RL.

BMJ Open. 2017 Jan 20;7(1):e013636. doi: 10.1136/bmjopen-2016-013636.

13.

Fixed-dose combination therapy for the prevention of cardiovascular disease.

de Cates AN, Farr MR, Wright N, Jarvis MC, Rees K, Ebrahim S, Huffman MD.

Cochrane Database Syst Rev. 2014 Apr 16;(4):CD009868. doi: 10.1002/14651858.CD009868.pub2. Review.

15.

ASPREE-NEURO study protocol: A randomized controlled trial to determine the effect of low-dose aspirin on cerebral microbleeds, white matter hyperintensities, cognition, and stroke in the healthy elderly.

Ward SA, Raniga P, Ferris NJ, Woods RL, Storey E, Bailey MJ, Brodtmann A, Yates PA, Donnan GA, Trevaks RE, Wolfe R, Egan GF, McNeil JJ; (Joint Senior authorship); on behalf of the ASPREE investigator group..

Int J Stroke. 2017 Jan;12(1):108-113. doi: 10.1177/1747493016669848.

PMID:
27634976
16.

Low-dose aspirin for primary prevention of cardiovascular events in Japanese patients 60 years or older with atherosclerotic risk factors: a randomized clinical trial.

Ikeda Y, Shimada K, Teramoto T, Uchiyama S, Yamazaki T, Oikawa S, Sugawara M, Ando K, Murata M, Yokoyama K, Ishizuka N.

JAMA. 2014 Dec 17;312(23):2510-20. doi: 10.1001/jama.2014.15690.

PMID:
25401325
17.

Adverse effects of low-dose aspirin in a healthy elderly population.

Silagy CA, McNeil JJ, Donnan GA, Tonkin AM, Worsam B, Campion K.

Clin Pharmacol Ther. 1993 Jul;54(1):84-9.

PMID:
8330469
18.

Risk of aspirin-associated major upper-gastrointestinal bleeding with enteric-coated or buffered product.

Kelly JP, Kaufman DW, Jurgelon JM, Sheehan J, Koff RS, Shapiro S.

Lancet. 1996 Nov 23;348(9039):1413-6.

PMID:
8937281
19.

Review article: gastrointestinal bleeding with low-dose aspirin - what's the risk?

Laine L.

Aliment Pharmacol Ther. 2006 Sep 15;24(6):897-908. Review.

20.

A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women.

Ridker PM, Cook NR, Lee IM, Gordon D, Gaziano JM, Manson JE, Hennekens CH, Buring JE.

N Engl J Med. 2005 Mar 31;352(13):1293-304.

Supplemental Content

Support Center